Soligenix, Inc. was recently invited to the annual Radiation Research Society meeting to present preliminary results from its gastrointestinal acute radiation syndrome (GI ARS) program.
Soligenix’s OrbeShield program is being evaluated as a potential medical countermeasure for both civilian and military personnel use. OrbeShield utilizes a proprietary formulation of beclomethasone 17,21-dipropionate (BDP), which includes immediate and delayed release tablets for GI tract treatment. OrbeShield is also being evaluated for the treatment of GI inflammation in pediatric Crohn’s disease and acute radiation enteritis.
The program was supported by grants from the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute for Allergy and Infectious Diseases (NIAID) that totaled approximately $34 million.
Presentation details will include gastrointestinal structure and function in a preclinical partial body irradiation in Göttingen minipigs, functional evaluations in GI acute radiation syndrome in Göttingen minipigs and rhesus monkeys, OrbeShield efficacy in a preclinical partial body irradiation in Göttingen minipigs, and gastrointestinal acute radiation syndrome in rhesus monkeys.
The Radiation Research Society’s annual meeting brings together worldwide experts from a variety of medical disciplines to discuss the advancement of radiation research, facilitating cooperative research in the disciplines of physics, chemistry, biology and medicine.
Soligenix is a late-stage biopharmaceutical company that develops and commercializes medical products to treat rare diseases where there is an unmet medical need.